Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 95 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H1 2016', provides in depth analysis on Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted pipeline therapeutics. 

The report provides comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)
- The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) Overview 9
Therapeutics Development 10
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Stage of Development 10
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Therapy Area 11
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Indication 12
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Companies 15
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Universities/Institutes 18
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Assessment 20
Assessment by Monotherapy/Combination Products 20
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Companies Involved in Therapeutics Development 27
Bionomics Limited 27
Catalyst Biosciences, Inc. 28
CoMentis, Inc. 29
FORUM Pharmaceuticals Inc. 30
Johnson & Johnson 31
Merck & Co., Inc. 32
NeuroDerm Ltd. 33
Neurodyn Inc. 34
Pfizer Inc. 35
Saniona AB 36
SK Biopharmaceuticals Co., Ltd. 37
Sunovion Pharmaceuticals Inc. 38
Vanda Pharmaceuticals Inc. 39
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Drug Profiles 40
(nicotine + opipramol hydrochloride) - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
AN-761 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
APN-1125 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
AQW-051 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
AVL-3288 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
AVL-8168 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
BNC-210 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
BNC-375 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Drugs to Agonize Alpha-7 Nicotinic Acetylcholine Receptor for Alzheimer's Disease and Schizophrenia - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
DSP-3748 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
encenicline hydrochloride - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
FRM-17874 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Gln-1062 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
GTS-21 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
JNJ-39393406 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
NBP-14 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
PNU-120596 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
SKL-15508 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
SKL-A4R - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Small Molecules to Agonize Alpha7 Acetylcholine Receptor for Cognitive Impairment - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Small Molecules to Agonize CHRNA7 for Central Nervous System - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Small Molecules to Agonize nAChR Alpha7 for Pain and Alzheimer's Disease - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Synthetic Peptide to Activate Neuronal Acetylcholine Receptor Subunit Alpha-7 for Alzheimer's Disease - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
TC-7020 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Dormant Projects 76
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Discontinued Products 80
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Featured News & Press Releases 81
Mar 24, 2016: FORUM Pharmaceuticals Provides Update on Encenicline Phase 3 Clinical Trial Program in Cognitive Impairment in Schizophrenia 81
Dec 08, 2015: Post Traumatic Stress Disorder Identified as Major New Market Opportunity for BNC210 82
Nov 11, 2015: FORUM Pharmaceuticals Announces Removal of Partial Clinical Hold on Phase 3 Encenicline Program for Cognitive Impairment in Schizophrenia 83
Sep 16, 2015: Bionomics Reports Positive Data from Phase 1 Multiple Ascending Dose Trial of BNC210 for Anxiety and Depression 83
Sep 14, 2015: FORUM Pharmaceuticals Updates Encenicline Phase 3 Clinical Trial Programs in Alzheimer's Disease and Cognitive Impairment in Schizophrenia 84
Jul 15, 2015: FORUM Pharmaceuticals Announces Publication of Encenicline Phase 2 Clinical Trial Results for Cognitive Impairment in Schizophrenia 85
Jun 22, 2015: FORUM Pharmaceuticals Receives FDA Fast Track Designation for Lead Compound Encenicline to Treat Cognitive Impairment in Schizophrenia 86
Jun 11, 2015: FORUM Pharmaceuticals Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial Program of Encenicline for Cognitive Impairment in Schizophrenia 87
Apr 20, 2015: Bionomics Initiates Phase II Clinical Trial Of BNC210 For Treatment Of Anxiety 88
Feb 02, 2015: Bionomics Begins Phase 1b Study With Anxiety Drug Bnc210 89
Jan 09, 2015: CoMentis and Anvyl Announce the Initiation of Clinical Trials for APN1125 for the Treatment of Schizophrenia 89
Nov 17, 2014: Bionomics to Present BNC210 at Society for Neuroscience Meeting 90
Nov 11, 2014: Bionomics to Progress BNC210 in Clinical Trials 90
Sep 09, 2014: Positive Phase 1a Outcome for Memogain 92
Feb 21, 2014: Neurodyn creates Memogain Advisory Board 93
Appendix 94
Methodology 94
Coverage 94
Secondary Research 94
Primary Research 94
Expert Panel Validation 94
Contact Us 94
Disclaimer 95

List of Tables

Number of Products under Development for, H1 2016 10
Number of Products under Development by Therapy Area, H1 2016 11
Number of Products under Development by Indication, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Early Stage Products, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Development by Companies, H1 2016 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H1 2016 18
Products under Investigation by Universities/Institutes, H1 2016 19
Assessment by Monotherapy/Combination Products, H1 2016 20
Number of Products by Stage and Mechanism of Action, H1 2016 22
Number of Products by Stage and Route of Administration, H1 2016 24
Number of Products by Stage and Molecule Type, H1 2016 26
Pipeline by Bionomics Limited, H1 2016 27
Pipeline by Catalyst Biosciences, Inc., H1 2016 28
Pipeline by CoMentis, Inc., H1 2016 29
Pipeline by FORUM Pharmaceuticals Inc., H1 2016 30
Pipeline by Johnson & Johnson, H1 2016 31
Pipeline by Merck & Co., Inc., H1 2016 32
Pipeline by NeuroDerm Ltd., H1 2016 33
Pipeline by Neurodyn Inc., H1 2016 34
Pipeline by Pfizer Inc., H1 2016 35
Pipeline by Saniona AB, H1 2016 36
Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 37
Pipeline by Sunovion Pharmaceuticals Inc., H1 2016 38
Pipeline by Vanda Pharmaceuticals Inc., H1 2016 39
Dormant Projects, H1 2016 76
Dormant Projects (Contd..1), H1 2016 77
Dormant Projects (Contd..2), H1 2016 78
Dormant Projects (Contd..3), H1 2016 79
Discontinued Products, H1 2016 80